2-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine | 916059-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine
• CAS: 916059-18-2
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: KVDYBBLXQWSVEN-UHFFFAOYSA-N

物化性质

• 沸点：
  294.7±30.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine 、 (2R,3S)-5-氧代-2-(2,4,5-三氟苯基)四氢-2H-吡喃-3-基)氨基甲酸叔丁酯 在 盐酸 、 癸硼烷 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 (2R,3S,5R)-5-(2-cyclopropyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2-(2,4,5-trifluorophenyl)oxan-3-amine
  参考文献：
  名称：

  Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23)

  摘要：

  A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.061
• 作为产物：
  描述：

  3-((二甲基氨基)亚甲基)-4-氧代吡咯烷-1-羧酸叔丁酯 在 盐酸 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 生成 2-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23)

  摘要：

  A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.061

文献信息

• [EN] CARM1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CARM1 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014144169A1

  公开（公告）日：2014-09-18

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARMl activity. Methods of using the compounds for treating CARM1 -mediated disorders are also described.

  本文提供了式（I）的化合物及其药用盐，以及药物组合物；其中X、R1、R1a、R2a、R2b、R2c、R2d如本文所定义，环HET是式（II）的6-成员单环杂环芳基环系统，其中L2、R13、G8、G10、G11和G12如本文所定义。本发明的化合物可用于抑制CARM1活性。还描述了使用这些化合物治疗CARM1介导的疾病的方法。
• Aminocyclohexanes as Dipeptidyl Peptidase-IV for the Treatment or Prevention of Diabetes
  申请人：Biftu Tesfaye

  公开号：US20090105284A1

  公开（公告）日：2009-04-23

  The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代氨基环己烷化合物，它们是二肽基肽酶-IV酶（“DPP-IV抑制剂”）的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的疾病中使用这些化合物和组合物的方法。
• Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Biftu Tesfaye

  公开号：US20100234403A1

  公开（公告）日：2010-09-16

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，其是二肽基肽酶IV酶的抑制剂，并且在治疗或预防涉及二肽基肽酶IV酶的疾病，例如糖尿病和特别是2型糖尿病中有用。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及二肽基肽酶IV酶的这些疾病中使用这些化合物和组合物。
• HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Biftu Tesfaye

  公开号：US20110224195A1

  公开（公告）日：2011-09-15

  The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式（I）的取代六元杂环化合物，它们是二肽基肽酶IV酶的抑制剂，并且在治疗或预防二肽基肽酶IV酶参与的疾病中有用，例如肥胖症和糖尿病，特别是2型糖尿病。本发明还涉及包括这些化合物的制药组合物以及在预防或治疗二肽基肽酶IV酶参与的这些疾病中使用这些化合物和组合物。
• CARM1 INHIBITORS AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20160039834A1

  公开（公告）日：2016-02-11

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 1a , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

  本文提供了式（I）的化合物及其药学上可接受的盐，以及它们的制药组合物；其中，X、R1、R1a、R2a、R2b、R2c、R2d的定义如本文所述，Ring HET是式（II）的6元单环杂芳基环系统，其中L2、R13、G8、G10、G11和G12的定义如本文所述。本发明的化合物对抑制CARM1活性有用。还描述了使用这些化合物治疗CARM1介导的疾病的方法。